From: Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosis
Cure
Improved
Invalidity or deterioration
Effective cases (Effective rate)
End of treatment(6 months)
1
16
3
17/20(85%)
End of follow-up (12 months)
0
14
14/17(82.35%)